US4844904A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Liposome composition
Assignee: Takeda Pharmaceutical Co Ltd
•
Filing: 1986-11-21
•
Granted: 1989-07-04
•
Expires: 2006-11-21
Abstract
Abstract Liposome compositions in which a drug is retained in stable condition are prepared by dispersing liposomes obtained by removal of a solvent from a drug-containing w/o emulsion in an aqueous solution having an osmotic pressure higher by at least 20 percent than the osmotic pressure of a solution used for entrapping the drug in said liposomes. This composition is conducive to a sustained therapeutic efficacy or a better delivery of the drug to a target organ.
Inventors
- 👤 Naoru Hamaguchi
- 👤 Katsumi Iga
- 👤 Yasuaki Ogawa
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 01:21
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/10; A61K9/127; A61K9/1277; Y; Y10; Y10S; Y10S436/00; Y10S436/829; Y10T; Y10T428/00; Y10T428/29; Y10T428/2982; Y10T428/2984
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
100 words
A liposome composition comprising (1) REV liposomes obtained by removing a solvent from a drug-containing w/o emulsion, said emulsion being obtained by emulsifying a solution used for entrapping the drug in liposomes with a chloroform-isopropyl ether solution containing dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine, wherein said solution used for entrapping the drug in the liposomes has an osmotic pressure of about 50 to 240 mOsm, and said drug is one selected from the group consisting of crisplatin, interleukin 2, manganese superoxide dismutase and superoxide dismutase-PEG, and (2) and aqueous disperse medium having an osmotic pressure which is about isotonic with the body fluid.
Claim 2
Dependent Claim
100 words
A liposome composition comprising (1) REV liposomes obtained by removing a solvent from a drug-containing w/o emulsion, said emulsion being obtained by emulsifying a solution used for entrapping the drug in liposomes with a chloroform-isopropyl ether solution containing dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine, wherein said solution used for entrapping the drug in the liposomes has an osmotic pressure of about 50 to 240 mOsm, and said drug is one selected from the group consisting of crisplatin, interleukin 2, manganese superoxide dismutase and superoxide dismutase-PEG, and (2) and aqueous disperse medium having an osmotic pressure which is about isotonic with the body fluid.
Claim 3
Dependent Claim
12 words
The composition according to claim 1, wherein the drug is interleukin 2.
Claim 4
Dependent Claim
11 words
The composition according to claim 1, wherein the drug is cisplatin.
Claim 5
Dependent Claim
16 words
The composition according to claim 1, wherein the drug is manganese superoxide dismutase or superoxide dismutase-PEG.
References Cited (Backward Citations)
US4217344A
Cited
US4235871A
Cited
US4377567A
Cited
EP0072234A1
Cited
US4594241A
Cited
EP0126580A2
Cited
US4515736A
Cited
US4565696A
Cited
US4652441A
Cited
GB2157172A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-07-03 | 1993-01-02 | 1993-07-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-07-03 | 1997-01-02 | 1997-07-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-07-03 | 2001-01-02 | 2001-07-04 | $7700.00 | Window Closed / Lapsed |